https://www.selleckchem.com/products/cb-5083.html
Of 41 patients radiographically evaluable for best overall response including 55 radiated and 23 unirradiated RECIST target lesions, 2 had complete responses (5%), 7 had partial responses (17%), 12 had stable disease (29%), and 20 had progression (49%). Median estimated PFS and OS are 3.0 months (95% CI 2.9-4.8) and 17.0 months (95% CI 6.8-undetermined), respectively. No patients with elevated pre-SBRT serum interleukin-8 experienced a response. SBRT to less than or equal to4 sites with nivolumab+urelumab or nivolumab+cabiralizumab for
Tycka om
Kommentar
Dela med sig
